Atherosclerosis
Volume 163, Issue 2 , Pages 287-296 , August 2002

Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux

  • Maryse Guerin

      Affiliations

    • Institut National de la Santé et de la Recherche Médicale (INSERM Unité 551), Hôpital de la Pitié, Pavillon Benjamin Delessert, 83 Boulevard de l'Hôpital, 75651 Paris, Cedex 13, France
    • Corresponding Author InformationCorresponding author. Tel.: +33-1-4217-7977; fax: +33-1-4582-8198
    • ,
  • Pascal Egger

      Affiliations

    • Institut National de la Santé et de la Recherche Médicale (INSERM Unité 551), Hôpital de la Pitié, Pavillon Benjamin Delessert, 83 Boulevard de l'Hôpital, 75651 Paris, Cedex 13, France
    • ,
  • Céline Soudant

      Affiliations

    • Institut National de la Santé et de la Recherche Médicale (INSERM Unité 551), Hôpital de la Pitié, Pavillon Benjamin Delessert, 83 Boulevard de l'Hôpital, 75651 Paris, Cedex 13, France
    • ,
  • Wilfried Le Goff

      Affiliations

    • Institut National de la Santé et de la Recherche Médicale (INSERM Unité 551), Hôpital de la Pitié, Pavillon Benjamin Delessert, 83 Boulevard de l'Hôpital, 75651 Paris, Cedex 13, France
    • ,
  • Arie van Tol

      Affiliations

    • Department of Biochemistry, Erasmus University, Rotterdam, The Netherlands
    • ,
  • Reynald Dupuis

      Affiliations

    • Pfizer, Paris, France
    • ,
  • M.John Chapman

      Affiliations

    • Institut National de la Santé et de la Recherche Médicale (INSERM Unité 551), Hôpital de la Pitié, Pavillon Benjamin Delessert, 83 Boulevard de l'Hôpital, 75651 Paris, Cedex 13, France

Received 15 November 2001 ,Accepted 30 January 2002.

References 

  1. Packard CJ. LDL subfractions and atherogenicity: an hypothesis from the University of Glasgow. Curr. Med. Res. Opin. 1996;13(7):379–390
  2. Chapman MJ, Goldstein S, Lagrange D, Laplaud PM. A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum. J. Lipid Res. 1981;22(2):339–358
  3. Patsch JR. Lipoprotein of the density 1.006–1.020 in the plasma of patients with type III hyperlipoproteinaemia in the postabsorptive state. Eur. J. Clin. Invest. 1975;5(1):45–55
  4. Meyer BJ, Caslake MJ, McConnell MM, Packard CJ. Two subpopulations of intermediate density lipoprotein and their relationship to plasma triglyceride and cholesterol levels. Atherosclerosis. 2000;153(2):355–362
  5. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler. Thromb. Vasc. Biol. 1997;17(12):3542–3556
  6. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am. J. Cardiol. 1998;81(4A):13B–17
  7. Nordestgaard BG, Zilversmit DB. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits. J. Lipid Res. 1988;29(11):1491–1500
  8. Hodis HN, Mack WJ, Dunn M, Liu C, et al.  Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation. 1997;95(8):2022–2026
  9. Shepherd J, Cobbe SM, Ford I, Isles CG, et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New Engl. J. Med. 1995;333(20):1301–1307
  10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344 (8934):1383–9.
  11. Griffin BA, Freeman DJ, Tait GW, Thomson J, et al.  Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994;106(2):241–253
  12. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, et al.  Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol. 1995;15(5):678–682
  13. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol. 1998;81(5):582–587
  14. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, et al.  Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. J. Am. Med. Assoc. 1996;275(2):128–133
  15. Alaupovic P, Heinonen T, Shurzinske L, Black DM. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels. Atherosclerosis. 1997;133(1):123–133
  16. Mohammadi A, Macri J, Newton R, Romain T, et al.  Effects of atorvastatin on the intracellular stability and secretion of apolipoprotein B in HepG2 cells. Arterioscler. Thromb. Vasc. Biol. 1998;18(5):783–793
  17. Guerin M, Lassel TS, Le Goff W, Farnier M, et al.  Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler. Thromb. Vasc. Biol. 2000;20(1):189–197
  18. Guerin M, Dolphin PJ, Chapman MJ. A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apoB-containing lipoprotein subspecies. Identification of preferential cholesteryl ester acceptors in human plasma. Arterioscler. Thromb. 1994;14(2):199–206
  19. Speijer H, Groener JE, van Ramshorst E, van Tol A. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis. 1991;90(2–3):159–168
  20. de la Llera Moya M, Atger V, Paul JL, Fournier N, et al.  A cell culture system for screening human serum for ability to promote cellular cholesterol efflux. Relations between serum components and efflux, esterification, and transfer. Arterioscler. Thromb. 1994;14(7):1056–1065
  21. Rothblat G, de la Llera Moya M, Atger V, Kellner-Weibel G, et al.  Cell cholesterol efflux: integration of old and new observations provides new insights. J. Lipid Res. 1999;40:781–796
  22. Isusi E, Aspichueta P, Liza M, Hernandez ML, et al.  Short- and long-term effects of atorvastatin, lovastatin and simvastatin on the cellular metabolism of cholesteryl esters and VLDL secretion in rat hepatocytes. Atherosclerosis. 2000;153(2):283–294
  23. Lamarche B, Tchernof A, Moorjani S, Cantin B, et al.  Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95(1):69–75
  24. Newnham HH, Barter PJ. Changes in particle size of high density lipoproteins during incubation with very low density lipoproteins, cholesteryl ester transfer protein and lipoprotein lipase. Biochim. Biophys. Acta. 1992;1125(3):297–304
  25. Crouse JR, Frohlich J, Ose L, Mercuri M, et al.  Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am. J. Cardiol. 1999;83(10):1476–1477 A7
  26. Mitchell A, Fidge N, Griffiths P. The effect of the HMG-CoA reductase inhibitor simvastatin and of cholestyramine on hepatic apolipoprotein mRNA levels in the rat. Biochim. Biophys. Acta. 1993;1167(1):9–14
  27. Martin G, Duez H, Blanquart C, Berezowski V, et al.  Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J. Clin. Invest. 2001;107(11):1423–1432
  28. Alam K, Meidell RS, Spady DK. Effect of up-regulating individual steps in the reverse cholesterol transport pathway on reverse cholesterol transport in normolipidemic mice. J. Biol. Chem. 2001;276(19):15641–15649
  29. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry. 1988;27(1):25–29
  30. von Eckardstein A, Jauhiainen M, Huang Y, Metso J, et al.  Phospholipid transfer protein mediated conversion of high density lipoproteins generates pre beta 1-HDL. Biochim. Biophys. Acta. 1996;1301(3):255–262

PII: S0021-9150(02)00037-0

Atherosclerosis
Volume 163, Issue 2 , Pages 287-296 , August 2002

Article Tools

* Image Usage & Resolution